Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InoviqASX:IIQ +5.71%10 Revenue per Share is A$0.01 as of Dec. 2025. GuruFocus rates ASX:IIQ with a GF Score™ of 10/100 and a GF Value™ of A$0.53 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, Inoviq ranks better than 85.94% on this metric.
Inoviq's revenue per share for the
six
months ended in Dec. 2025 was A$0.00.
Inoviq's revenue per share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.01.
Warning Sign:
Inoviq Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Inoviq was -16.70% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 18.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Inoviq's Revenue per Share or its related term are showing as below:
ASX:IIQ'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -93.5 Med: -26.95 Max: 144.4
Current: 18.6
During the past 13 years, Inoviq's highest 3-Year average Revenue Per Share Growth Rate was 144.40% per year. The lowest was -93.50% per year. And the median was -26.95% per year.
ASX:IIQ's 3-Year Revenue Growth Rate is ranked better than 85.94% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs ASX:IIQ: 18.60
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Inoviq Revenue per Share Related Terms
Inoviq Revenue per Share Historical Data
* Premium members only.
The historical data trend for Inoviq's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IIQ vs TMO, DHR, NTRA: Revenue per Share Comparison
For the Diagnostics & Research subindustry, Inoviq's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inoviq PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's PS Ratio distribution charts can be found below:
* The bar in red indicates where Inoviq's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Inoviq's Revenue Per Share for the fiscal year that ended in Jun. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inoviq (ASX:IIQ) has a Revenue per Share of A$0.01 as of Dec. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on Inoviq and its competitors. According to the industry distribution chart, Inoviq ranks #27 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 14.1%.
Is Inoviq's Revenue per Share too high?
Inoviq's current Revenue per Share is A$0.01. Based on the distribution chart, Inoviq ranks #27 out of 192 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Inoviq has a GF Score™ of 10/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inoviq's Revenue per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Inoviq ranks #27 out of 192 companies for Revenue per Share. This places Inoviq in the top 14% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 2.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Diagnostics & Research company?
The median Revenue per Share among Medical Diagnostics & Research companies is 2.05, based on 192 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Inoviq and its competitors. For the Medical Diagnostics & Research industry, the median Revenue per Share is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inoviq's current Revenue per Share is A$0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Based on GuruFocus' analysis, Inoviq (ASX:IIQ) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.53, compared to a current price of A$0.19 — trading 65.1% below its estimated fair value. The current Revenue per Share is A$0.01. Inoviq's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Inoviq (ASX:IIQ), the current Revenue per Share is A$0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inoviq (ASX:IIQ) Overvalued in 2026?
Based on GuruFocus' analysis, Inoviq stock appears to be undervalued.
The current stock price of A$0.19 is trading 65.1% below its estimated GF Value™ of A$0.53.
GuruFocus considers Inoviq to be Possible Value Trap.
Key valuation signals for ASX:IIQ:
Revenue per Share: A$0.01
GF Value™: A$0.53 vs. price of A$0.19 (65.1% below fair value)
No single metric tells the full story. See the ASX:IIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
10GF Score
Get the complete analysis for ASX:IIQ
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IIQ has been successfully added to your 
